齐达斯和Bioeq推出NUFYMCO®,这是FDA批准的用于治疗眼病的新生物仿制药,旨在降低治疗成本. Zydus and Bioeq launch NUFYMCO®, a new FDA-approved biosimilar for eye diseases, aiming to lower treatment costs.

在2025年12月18日美国林业发展局批准后,Zydus生命科学公司和Bioeque AG公司合作将NUFYMCO商业化,这是一个与Lucentis(ranibizumab)类似的生物产品。 Zydus Lifesciences and Bioeq AG have partnered to commercialize NUFYMCO®, a biosimilar to Lucentis® (ranibizumab), following U.S. FDA approval on December 18, 2025. Bioeq将管理开发、制造和供应,Zydus则负责美国商业化。 Bioeq will manage development, manufacturing, and supply, while Zydus handles U.S. commercialization. 该生物类似药治疗湿性年龄相关黄斑变性和糖尿病黄斑水肿等眼疾。 The biosimilar treats eye conditions like wet age-related macular degeneration and diabetic macular edema. 这种生物相似的美国市场估计为2.1亿美元。 The U.S. market for this biosimilar is estimated at $210 million. 协议扩大了Zydus的美国生物类同组合,旨在改善人们获得负担得起的眼科治疗的机会。 The deal expands Zydus’ U.S. biosimilar portfolio and aims to improve access to affordable ophthalmology treatments.